Urologie Labor

2024 - 2026

• Ladurner M, Ameismeier T, Klocker H, Steiner E, Hauffe H, Aigner GP, et al. An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy. J Clin Endocrinol Metab. 2025;110(6):1689-1700.
  
  
• van Creij NCH, Klinglmair G, Gruber L, Partl A, Zeimet AG, Santer FR, et al. Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report. Ther Adv Urol. 2025;17:17562872251322648.
  
  
• Törzsök P, Santer FR, Kunz Y, van Creij NCH, Tymoszuk P, Klinglmair G, et al. Biological and therapeutic implications of sex hormone-related gene clustering in testicular cancer. Basic Clin Androl. 2025;35(1):8.
  
  
• Damisch E, Brunner E, Nommensen L, Neumann L, Fotakis G, Trajanoski Z, et al. Optimised dissociation and multimodal profiling of prostate cancer stroma reveal fibromuscular cell heterogeneity with clinical correlates. Front Cell Dev Biol. 2025;13:1653780.
  
  
• Brunner E, Damisch E, Groninger ME, Baschieri F, Tyckaert F, Nommensen L, et al. Unraveling the YAP1-TGFβ1 axis: a key driver of androgen receptor loss in prostate cancer-associated fibroblasts. J Exp Clin Cancer Res. 2025;45(1):11.
  
  
• Artamonova N, Galleé L, Neuwirt H, Heimdörfer D, Ladurner M, Giannini G, et al. The Clinical Trajectory of Prostate Cancer Patients Harboring Rare Histological Subtypes-A Retrospective Cohort Trial. Clin Genitourin Cancer. 2025;23(4):102350.
  
  
• Atas E, Berchtold K, Schlederer M, Prodinger S, Sternberg F, Pucci P, et al. The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer. Mol Cancer. 2025;24(1):134.
  
  
• Schoepf AM, Gebhart M, Federspiel M, Heidegger I, Puhr M, Hotze M, et al. Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives. J Med Chem. 2025;68(1):287-306.
  
  
• van de Merbel AF, van der Mark MH, Aalders T, Puhr M, Mehra N, Schalken J, et al. Anti-neoplastic effects of the antipsychotic drug penfluridol in preclinical prostate cancer models. Front Oncol. 2025;15:1685758.
  
  
• Roa FJ, Roubelakis M, Paschidis K, van Creij NCH, Handle F, Makridakis M, et al. Repurposing Amiodarone for Bladder Cancer Treatment. Cancer Res Commun. 2025;5(6):906-920.
  
  
• Adzavon YM, Culig Z, Sun Z. Interactions between androgen and IGF1 axes in prostate tumorigenesis. Nat Rev Urol. 2025;22(5):268-275.
  
  
• Guzman J, Hart M, Weigelt K, Neumann A, Aigner A, Andolfi C, et al. The MicroRNA miR-454 and the mediator complex component MED12 are regulators of the androgen receptor pathway in prostate cancer. Sci Rep. 2025;15(1):10272.
  
  
• Drápela S, Kvokačková B, Slabáková E, Kotrbová A, Gömöryová K, Fedr R, et al. Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cells. Cell Oncol (Dordr). 2025;48(1):205-218.
  
  
• Frantzi M, Morillo AC, Lendinez G, Blanca A, Lopez Ruiz D, Parada J, et al. Validation of a Urine-Based Proteomics Test to Predict Clinically Significant Prostate Cancer: Complementing mpMRI Pathway. Pathobiology. 2025;92(2):99-108.
  
  
• Culig Z. Insights from the Seminal Findings from Puhr et al on the Mechanisms of Docetaxel Resistance in Prostate Cancer. Am J Pathol. 2025;195(4):612-614.
  
  
• Pichler R, van Creij NCH, Subiela JD, Cimadamore A, Caño-Velasco J, Tully KH, et al. Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease. Actas Urol Esp (Engl Ed). 2025;49(5):501719.
  
  
• van Creij NCH, Subiela JD, Pichler R. Re: Cariss E. Chu, Ziyu Chen, Karissa Whiting, et al. Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma. Eur Urol. 2025;88(6):e117-e118.
  
  
• Pichler R, van Creij NCH, Mertens LS, Del Giudice F, Koll F, Soria F, et al. FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma. Eur Urol Oncol. 2026;9(2):220-226.
  
  
• Neuwirt H, Eder IE, Gauckler P, Horvath L, Koeck S, Noflatscher M, et al. Impact of familiarity with the format of the exam on performance in the OSCE of undergraduate medical students - an interventional study. BMC Med Educ. 2024;24(1):179.
  
  
• Pinkeova A, Tomikova A, Bertokova A, Fabinyova E, Bartova R, Jane E, et al. Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study. PLoS One. 2024;19(3):e0300430.
  
  
• Andolfi C, Bartolini C, Morales E, Gündoğdu B, Puhr M, Guzman J, et al. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer. Endocrinology. 2024;165(10):bqae114.
  
  
• Van Goubergen J, Peřina M, Handle F, Morales E, Kremer A, Schmidt O, et al. Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression. Mol Oncol. 2025;19(2):496-518.
  
  
• Artamonova N, Kafka M, Faiss L, Avetisyan D, Puche Sanz I, La Bombarda G, et al. Impact of Renin-Angiotensin System Inhibitors on Disease Characteristics in Patients with Localized Prostate Cancer Treated with Radical Prostatectomy: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study. Eur Urol Open Sci. 2024;69:105-111.
  
  
• Papachristodoulou A, Heidegger I, Virk RK, Di Bernardo M, Kim JY, Laplaca C, et al. Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. Eur Urol. 2024;85(4):361-372.
  
  
• Wang J, Wei J, Pu T, Zeng A, Karthikeyan V, Bechtold B, et al. Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. EClinicalMedicine. 2024;5(2):101388.
  
  
• Beier AK, Ebersbach C, Siciliano T, Scholze J, Hofmann J, Hönscheid P, et al. Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer. Oncogene. 2024;43(26):2038-2050.
  
  
• Mehralivand S, Thomas C, Puhr M, Claessens F, van de Merbel AF, Dubrovska A, et al. New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium. J Transl Med. 2024;22(1):71.
  
  
• Heidegger I, Frantzi M, Salcher S, Tymoszuk P, Martowicz A, Gomez-Gomez E, et al. Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature. Eur Urol Oncol. 2025;8(3):652-662.
  
  
• Israel JS, Marcelin LM, Thomas C, Szczyrbová E, Fuessel S, Puhr M, et al. Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium. J Exp Clin Cancer Res. 2024;43(1):194.
  
  
• Brandt MP, Vakhrusheva O, Hackl H, Daher T, Tagscherer K, Roth W, et al. Inhibition of the Sterol Regulatory Element Binding Protein SREBF-1 Overcomes Docetaxel Resistance in Advanced Prostate Cancer. Am J Pathol. 2024;194(11):2150-2162.
  
  
• Hönscheid PV, Baretton GB, Puhr M, Siciliano T, Israel JS, Stope MB, et al. Prostate Cancer's Silent Partners: Fibroblasts and Their Influence on Glutamine Metabolism Manipulation. Int J Mol Sci. 2024;25(17):9275.
  
  
• Israel JS, Marcelin LM, Mehralivand S, Scholze J, Hofmann J, Stope MB, et al. The impact of androgen-induced translation in modulating androgen receptor activity. Cell Death Discov. 2024;19(1):111.
  
  
• Culig Z, Puhr M. Androgen Receptor-Interacting Proteins in Prostate Cancer Development and Therapy Resistance. Am J Pathol. 2024;194(3):324-334.
  
  
• Eigentler A, Handle F, Schanung S, Degen A, Hackl H, Erb HHH, et al. Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts. Oncogene. 2024;43(4):235-247.
  
  
• Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, et al. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024;27(3):451-456.
  
  
• Hemminki K, Kiemeney LA, Morgans AK, Rannikko A, Pichler R, Hemminki O, et al. Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes. Eur Urol Open Sci. 2024;69:13-20.
  
  
• Heimdörfer D, Artamonova N, Culig Z, Heidegger I. Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer. J Cancer Res Clin Oncol. 2024;150(10):462.
  
  
• Heidegger I, Culig Z. Clinical and basic research implications of the article 'IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer'. Endocr Relat Cancer. 2024;31(5):e230362.
  
  
• Guzman J, Weigelt K, Neumann A, Tripal P, Schmid B, Winter Z, et al. NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers. BMC Cancer. 2024;24(1):346.
  
  
• Fracassi G, Lorenzin F, Orlando F, Gioia U, D'Amato G, Casaramona AS, et al. CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer. J Clin Invest. 2024;135(4):e179393.
  
  
• Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM, et al. Real-world Outcomes and Predictive Biomarkers for ^177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study. Eur Urol Oncol. 2024;7(3):421-429.
  
  
• Marra G, Lesma F, Montefusco G, Filippini C, Olivier J, Affentranger A, et al. Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort. Eur Urol Open Sci. 2024;68:32-39.

2020 - 2023

• Kang J, La Manna F, Bonollo F, Sampson N, Alberts I L, Mingels C, Afshar-Oromieh A, Thalmann GN, Karkampouna S (2022). Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer; Cancer Lett 530: 156-169.
  
  
• Furlan T, Kirchmair A, Sampson N, Puhr M, Gruber M, Trajanoski Z, Santer FR, Parson W, Handle F, Culig Z (2021). MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors; Am J Pathol 191: 1094-1107
  
  
• Gruber M, Ferrone L, Puhr M, Santer FR, Fulran T, Eder IE, Sampson N, Schäfer G, Handle F, Culig Z (2020). p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer; Endocr Relat Cancer 27: 187-198.
  
  
• Gruber M, Handle F, Culig Z (2020). The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells; Prostate 80:267-273.
  
  
• Pichler R, Lindner AK, Comperat E, Obrist P, Schäfer G, Todenhöfer T, Horninger W, Culig Z, Untergasser G (2020). Amplification of 7p12 is associated with pathologic nonresponse to neodjuvant chemotherapy in muscle-invasive bladder cancer; Am J Pathol 190:442-452.
  
  
• Drapela S, Khisariya P, van Weerden WM, Fedr R, Suchankova T, Buzova D, Cerveny J, Hampl A, Puhr M, Watson WR, Culig Z, Krejci L, Paruch K, Soucek K (2020). The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe; Mol Oncol 14:2487-2503.
  
  
• Erb HHH, Bodenbender J, Handle F, Diehl T, Donix L, Tsaur I, Gleave M, Haferkamp A, Huber J, Fuessel S, Juengel E, Culig Z, Thomas C (2020). Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer; PLoS One 15:e0237248.
  
  
• Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schlederer M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, Stangl-Kremser J, Hassler MR, Kramer G, Shariat SF, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangemann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L (2021). Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer; Int J Cancer 148:731-747.
  
  
• Tulchiner G, Staudacher N, Fritz J, Radmayr C, Culig Z, Horninger W, Pichler R (2021). The COVID19 pandemic gap and its influence o.n oncologic outcomes of bladder cancer; Cancers (Basel) 13:1754
  
  
• Tulchiner G, Brunner A, Schmidinger M, Staudacher N; Orme JJ, Thurnher M, Horninger W, Culig Z, Pichler R (2021). CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal carcinoma; BJU Int 128:29-32.
  
  
• Erb HHH, Culig Z, Stope MB (2021). IL-4 counteracts the cytotoxic effects of peripheral blood mononuclear cells on hormone-sensitive prostate cancer cells; In Vivo 35:1973-1977.
  
  
• Offermann A, Kang D, Watermann C, Weingart A, Hupe MC, Saraji A, Stegmann-Frehse J, Kruper R, Schüle R, Pantel K, Taubert H, Duensing S, Culig Z, Aigner A, Klapper W, Jonigk D, Philipp Kühnel M, Merseburger AS, Kirfel J, Sailer V, Perner S (2021). Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases; Carcinogenesis 42:1475-1484.
  
  
• Offermann A, Joerg V, Becker F, Roesch MC, Lemster AL, Tharun L, Behrends J, Merseburger AS, Culig Z, Sailer V, Brägelmann J, Kirfel J, Perner S (2022). Inhibition of cyclin-dependent kinase 8/Cyclin-dependent kinase 19 suppresses its pro-oncogenic effects in prostate cancer; Am J Pathol 192:813-823.
  
  
• Vakhnusheva O, Erb HHH, Bräunig V, Markowitsch SD, Schupp P, Baer PC, Slade KS, Thomas A, Tsaur I, Puhr M, Culig Z, Cinati J Jr., Michaelis M, Efferth T, Haferkamp A, Juengel E (2022). Artesunate inhibits the growth behavior of docetaxel-resistant prostate cancer cells;  Front Oncol 12:789284.
  
  
• Limberger T, Schlederer M, Trachtova K, Garces de Los Fayos Alonso I, Yang J, Högler S, Sternberg C, Bystry V, Oppelt J Tichy B, Schmeidl M, Kodajova P, Jäger A, Neubauer HA, Oberhuber M, Schmalzbauer BS, Pospisilova S, Dolznig H, Wadsak W, Culig Z, Turner SD, Egger G, Lagger S, Kenner L (2022). KMT2c methyltransferse domain regulated INK4A expression suppresses prostate cancer metastasis; Mol Cancer 21:89, 2022.
  
  
• Lindner AK, Furlan T, Orme JJ, Tulchiner G, Staudacher N, D´Andrea D, Culig Z, Pichler R (2022). HUS1 as a potential therapeutic target in urothelial cancer; J Clin Med 11:2208.
  
  
• Muresan XM, Slabakova E, Prochazkova J, Drapela S, Fedr R, Pickova M, Vacek O, VIchova R, Suchankova T, Bouchal J, Kurfurstova D, Kral M, Hulinova T, Sykora RP, Student V, Hejret V, van Weerden WM, Puhr M, Pustka V, Potesil D, Zdrahal Z, Culig Z, Soucek K (2022). Toll-like receptor 3 overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis; Am J Pathol 192:1321-1335.
  
  
• Frantzi M, Heidegger I, Roesch MC, Gomez-Gomez E, Steiner E, Vlahou A, Mullen W, Guler I, Merseburger AS, Mischak H, Culig Z (2022). Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer; World J Urol 40:2195-2203.
  
  
• Mengual L, Frantzi M, Mokou M, Ingelmo-Torres M, Vlaming M, Merseburger AS, Roesch MC, Culig Z, Alcaraz A, Vlahou A, Mischak H, van der Heijden AG (2022). Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients; Br J Cancer 127:2043-2051.
  
  
• Frantzi M, Culig Z, Heidegger I, Mokou M, Latosinska A, Roesch MC, Merseburger AS, Makridakis M, Vlahou A, Blanca-Pedregosa A, Carrasco-Valente J, Mischak H, Gomez-Gomez E (2023). Mass spectrometry-based biomarkers to detect prostate cancer: a multicentric study based on non-invasive urine collection without prior digital rectal examination; Cancers (Basel) 15:1166.
  
  
• Pardella E, Pranzini E, Nesi L, Parri M, Spatafora P, Torre E, Muccilli A, Castiglione F, Fambrini M, Sorbi F, Cirri P, Caselli A, Puhr M, Klocker H, Serni S, Raugei G, Magherini F, Taddei ML (2022). Therapy-induced stromal senescence promoting aggressiveness of prostate and ovarian cancer; Cells 11:4026.
  
  
• Baier AK, Puhr M, Stope MB, Thomas C, Erb H (2023). Metabolic changes during prostate cancer development and progression; J Cancer Res Clin Oncol 149:2259-2270.
  
  
• Csizmarik A, Keresztes D, Nagy N, Bracht T, Sitek B, Witzke K, Puhr M, Tomyi I, Lazar J, Takacs L, Kramer G, Sevcenco S, Maj-Hes A, Juranyi Z, Hadaschik B, Nyrady P, Szarvas T (2022): Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer; Int J Cancer 15:1405-1419.
  
  
• Kersztes D, Csizmarik A, Nagy N, Modos O, Fazekas T, Bracht T, Sitek B, Witzke K, Puhr M, Sevonico S, Kramer G, Shariat S, Kuronya Z, Takacs L, Tornyi I, Lazar J, Hadaschik B, Laszik A, Szucs M, Nyriady P, Szarvas T (2022). Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer; J Cell Mol Med 26:1332-1337.
  
  
• Kalogirou C, LInxweiler J, Schmucker P, Snabjornsson MT, Schmitz W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A (2021). MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer; Nat Commun 20:5066.
  
  
• Puhr M, Eigentler A, Handle F, Hackl H, Ploner C, Heidegger I, Schaefer G, Brandt MP, Hoefer J, van der Pluijm G, Klocker H (2021). Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer; Oncogene 40:3087-3100.
  
  
• Kafka M, Gruber R, Neuwirt H, Ladurner M, Eder IE (2022). Long-term treatment with simvastatin  leads to reduced migration capacity in prostate cancer cells; Biomedicines 11:29.
  
  
• Ladurner M, Wieser M, Eigentler A, Seewald M, Dobler G, Neuwirt H, Kafka M, Heidegger I, Horninger W, Bektic J, Klocker H, Obrist P, Eder IE (2023). Validation of cell-free RNA and circulating tumor cells for molecular marker analysis in metastatic prostate cancer; Biomedicines 12:1004.
  
  
• Kafka M, Mayr F, Temmi V, Möller G, Adamski J, Höfer J, Schwaiger S, Heidegger I, Matusczak B, Schuster D, Klocker H, Bektic J, Stuppner H, Eder IE (2020). Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer; Cancers (Basel) 12:2092.
  ​
• Neuwirt H, Bouchal J, Kharashvili G, Ploner C, Jöhrer K, Pitterl F, Weber A, Klocker H, Eder IE (2020). Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis; Cell Commun Signal 18:11.